Transcatheter aortic valve replacement (TAVR) has transformed the treatment of critical aortic stenosis, particularly for those patients whose surgical operative risks are high. However, pre-TAVR vascular mapping with CT requires 40-120 mls of iodinated contrast, which in older patients with renal impairment increases the risk of acute renal injury that portends poor prognosis. We demonstrated that ferumoxytol MRA can provide reliable vascular mapping in patients with renal impairment undergoing TAVR evaluation, without exposure to iodinated or gadolinium contrast agents.
This abstract and the presentation materials are available to members only; a login is required.